Cyp.Ax
Cyprium Mining Limited (CYP.AX) is a biotechnology company focused on the development of novel therapies for the treatment of rare diseases, primarily through its research and development activities in the pharmaceutical sector.
Business. Cyprium Mining Limited (CYP.AX) is a biotechnology company focused on the development of novel therapies for the treatment of rare diseases, primarily through its research and development activities in the pharmaceutical sector.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Cyprium Mining Limited (CYP.AX) is a biotechnology company focused on the development of novel therapies for the treatment of rare diseases, primarily through its research and development activities in the pharmaceutical sector.
Cyprium Mining Limited has a capital structure characterized by a debt-to-equity ratio of 0.0, indicating no long-term debt obligations, and a current ratio of 4.4, suggesting strong short-term liquidity. The company's total equity stands at 5,981,740 AUD, while its total liabilities are 1,216,180 AUD. The company's liquidity position is assessed as low, but this is not due to any immediate filing-based liquidity flags.
The company's profitability is currently negative, with a return on equity of -1.57 and a return on assets of -1.30, both significantly below the industry median for biotechnology firms. The operating income is -9,383,180 AUD, and the net income is -9,390,590 AUD, indicating a substantial loss for the period. These figures suggest that the company is not generating returns that meet the expectations of its industry peers.
Cyprium Mining Limited's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. The company's revenue is entirely derived from its operations in the biotechnology and medical research sector, with no indication of international revenue streams.
The company's growth trajectory is uncertain, with a projected revenue of 2,100,000 AUD for the current fiscal year, which is a decrease from the reported revenue of 227,700 AUD. The mean EPS estimate is -3.60 AUD, indicating continued losses. The company's capital expenditure is minimal at -50,000 AUD, suggesting limited investment in new projects or expansion.
The risk assessment for Cyprium Mining Limited indicates a low probability of dilution, with no immediate filing-based dilution flags detected. The company's liquidity risk is also assessed as low, but the credit risk is not explicitly mentioned. The company's operating cash flow is negative at -8,720,340 AUD, and the free cash flow is -9,157,630 AUD, indicating a lack of cash generation.
Recent events and filings do not show any significant changes in the company's operations or financial position. The company has not issued any new shares or taken on additional debt, and there are no recent regulatory actions or legal proceedings that have been disclosed. The company's analyst estimates suggest a mean recommendation of 2.00, with one buy recommendation and no strong buy or sell recommendations.
- Cyprium Mining Limited is a biotechnology company with a strong short-term liquidity position but no long-term debt.
- The company is currently unprofitable, with a negative return on equity and return on assets.
- The company's revenue is concentrated in a single business segment, with no geographic diversification.
- The company's growth trajectory is uncertain, with a projected revenue decrease and continued losses.
- The company has a low probability of dilution and no immediate filing-based liquidity or dilution flags.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- CYP.AX Market data — financials · 2026-05-27
- Cynata Therapeutics Ltd Market data — analyst estimates · 2026-05-27